The role of oxytocin in the pathogenesis of endometriosis: various aspects of the problem

Maria I. Yarmolinskaya, Vladislav V. Khobets
In: Journal of obstetrics and women's diseases · 2019 · vol. 68(3) , pp. 89–98 · doi:10.17816/jowd68389-98 · W2957871544
article OA: hybrid CC0 ⤵ 5 in-corpus citations
🔓 Open OA copy View on OpenAlex View at publisher

Abstract

Hypothesis/aims of study. Endometriosis is a chronic recurrent disease that leads to a significant decrease in the quality of life. Despite the existing therapeutic methods, the prevalence of the disease is steadily increasing. The pathogenesis of endometriosis has not been studied enough, resulting in failure to achieve high efficiency in its treatment. Due to chronic pelvic pain, infertility, and dissatisfaction with the quality of life, women suffering from endometriosis present with various mental disorders of different degrees of severity. This study aims to summarize the literature discussing the possible role of oxytocin in the pathogenesis of both endometriosis and affective disorders. Study design, materials, and methods. Literature data for the period from 1986 to 2019. Conclusion. The role of oxytocin in the pathogenesis of endometriosis needs further study. Oxytocin receptor antagonists can be considered promising in the treatment of this medical condition, as well as in prevention and management of affective disorders in patients with endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paininfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (70)

Cited by (5)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK